基于系统综述和网络荟萃分析结果选择一线间变性淋巴瘤激酶（ALK）酪氨酸激酶抑制剂（TKI）

{"title":"基于系统综述和网络荟萃分析结果选择一线间变性淋巴瘤激酶（ALK）酪氨酸激酶抑制剂（TKI）","authors":"E. Urbanska","doi":"10.21037/pcm-23-11","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":74487,"journal":{"name":"Precision cancer medicine","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Choice of first-line anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) based on the results of a systematic review and network meta-analysis\",\"authors\":\"E. Urbanska\",\"doi\":\"10.21037/pcm-23-11\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":74487,\"journal\":{\"name\":\"Precision cancer medicine\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Precision cancer medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21037/pcm-23-11\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Precision cancer medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21037/pcm-23-11","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}